

Nabeel B Nabulsi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1499126/publications.pdf>

Version: 2024-02-01

147
papers

6,112
citations

76326

40
h-index

88630

70
g-index

149
all docs

149
docs citations

149
times ranked

5904
citing authors

#	ARTICLE	IF	CITATIONS
1	Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer ¹¹ C-TASP699. <i>Journal of Nuclear Medicine</i> , 2022, 63, 609-614.	5.0	7
2	Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2022, 111, 44-53.	3.1	25
3	A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [18F]SDM-16. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1482-1496.	6.4	16
4	Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory ¹¹ C- β -galactosidase positron emission tomography study in humans. <i>Addiction Biology</i> , 2022, 27, e13123.	2.6	16
5	Translational PET Imaging of Spinal Cord Injury with the Serotonin Transporter Tracer [11C]AFM. <i>Molecular Imaging and Biology</i> , 2022, , 1.	2.6	0
6	Nicotine patch alters patterns of cigarette smoking-induced dopamine release: Patterns relate to biomarkers associated with treatment response. <i>Nicotine and Tobacco Research</i> , 2022, , .	2.6	1
7	Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [¹¹ C]UCB β . <i>Alzheimer's and Dementia</i> , 2022, 18, 2527-2536.	0.8	55
8	Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. <i>Molecular Psychiatry</i> , 2022, 27, 2273-2281.	7.9	25
9	Assessment of gray matter microstructure and synaptic density in Alzheimer's disease: A multimodal imaging study with DWI and SV2A PET. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, S26.	1.2	0
10	Feasibility of imaging synaptic density in the human spinal cord using [11C]UCB-J PET. <i>EJNMMI Physics</i> , 2022, 9, 32.	2.7	3
11	Differences in the association between kappa opioid receptors and pain among Black and White adults with alcohol use disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 1348-1357.	2.4	2
12	Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3679-3691.	6.4	4
13	Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. <i>Molecular Psychiatry</i> , 2021, 26, 3192-3200.	7.9	32
14	Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving. <i>Molecular Psychiatry</i> , 2021, 26, 5053-5060.	7.9	17
15	Binding of the synaptic vesicle radiotracer [¹¹ C]UCB-J is unchanged during functional brain activation using a visual stimulation task. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1067-1079.	4.3	28
16	Simplified Quantification of ¹¹ C-UCB-J PET Evaluated in a Large Human Cohort. <i>Journal of Nuclear Medicine</i> , 2021, 62, 418-421.	5.0	19
17	First-in-Human Evaluation of ¹⁸ F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A. <i>Journal of Nuclear Medicine</i> , 2021, 62, 561-567.	5.0	60
18	Longitudinal imaging of metabotropic glutamate 5 receptors during early and extended alcohol abstinence. <i>Neuropsychopharmacology</i> , 2021, 46, 380-385.	5.4	7

#	ARTICLE	IF	CITATIONS
19	First-in-Human Assessment of ¹¹ C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 553-560.	5.0	35
20	PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain. <i>Cerebral Cortex</i> , 2021, 31, 2787-2798.	2.9	5
21	Association of A β 2 deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [¹¹ C]UCB-J. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 11.	6.2	53
22	Assessment of test-retest reproducibility of [¹⁸ F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1327-1338.	6.4	23
23	Dopamine D2/3 receptor availability in cocaine use disorder individuals with obesity as measured by [¹¹ C]PHNO PET. <i>Drug and Alcohol Dependence</i> , 2021, 220, 108514.	3.2	1
24	Comparison of [¹¹ C]UCB-J and [¹⁸ F]FDG PET in Alzheimer's disease: A tracer kinetic modeling study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2395-2409.	4.3	43
25	Synaptic density is associated with cognitive performance in early Alzheimer's disease: a PET imaging study with [¹¹ C]UCB-J. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, S119-S120.	1.2	1
26	Principal component analysis of synaptic density measured with [¹¹ C]UCB-J PET in Alzheimer's disease. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, S47-S48.	1.2	0
27	Imaging the Effect of Ketamine on Synaptic (SV2A) Density. <i>Biological Psychiatry</i> , 2021, 89, S35.	1.3	0
28	In vivo evidence of lower synaptic vesicle density in schizophrenia. <i>Molecular Psychiatry</i> , 2021, 26, 7690-7698.	7.9	51
29	Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [¹⁸ F]FPEB PET. <i>NeuroImage</i> , 2021, 238, 118217.	4.2	10
30	Assessment of transient dopamine responses to smoked cannabis. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108920.	3.2	4
31	PET Imaging of Synaptic Vesicle Protein 2A. , 2021, , 993-1019.		10
32	Imaging brain cortisol regulation in PTSD with a target for 11 β -hydroxysteroid dehydrogenase type 1. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	10
33	Evaluation of quantitative modeling methods in whole-body, dynamic [¹¹ C]-erlotinib PET. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 143-153.	1.0	3
34	First in-human PET study and kinetic evaluation of [¹⁸ F]AS2471907 for imaging 11 β -hydroxysteroid dehydrogenase type 1. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 695-704.	4.3	10
35	PET Imaging of Pancreatic Dopamine D ₂ and D ₃ Receptor Density with ¹¹ C-(+)-PHNO in Type 1 Diabetes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 570-576.	5.0	19
36	Assessment of a white matter reference region for ¹¹ C-UCB-J PET quantification. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1890-1901.	4.3	77

#	ARTICLE	IF	CITATIONS
37	Measuring the effects of ketamine on mGluR5 using [¹⁸ F]FPEB and PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 2254-2264.	4.3	13
38	In vivo 5-HT ₆ and 5-HT _{2A} receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [¹¹ C]GSK215083 PET. <i>Psychiatry Research - Neuroimaging</i> , 2020, 295, 111007.	1.8	17
39	Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [¹¹ C]UCBâ€ positron emission tomography study. <i>Epilepsia</i> , 2020, 61, 2183-2193.	5.1	51
40	[¹¹ C]Methionine and [¹¹ C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis. <i>Molecular Imaging</i> , 2020, 19, 153601212096866.	1.4	12
41	In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimerâ€™s disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037791.	0.8	1
42	PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimerâ€™s disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037792.	0.8	0
43	¹¹ Câ€PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimerâ€™s disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043584.	0.8	0
44	Association between cerebral amyloid accumulation and synaptic density in Alzheimerâ€™s disease: A multitracer PET study. <i>Alzheimer's and Dementia</i> , 2020, 16, e043631.	0.8	0
45	Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimerâ€™s disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044211.	0.8	2
46	Validation of a simplified tissueâ€toâ€reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimerâ€™s disease using [¹¹ C]UCBâ€ PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e045928.	0.8	1
47	In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. <i>Alzheimer's and Dementia</i> , 2020, 16, 974-982.	0.8	170
48	PTSD is associated with neuroimmune suppression: evidence from PET imaging and postmortem transcriptomic studies. <i>Nature Communications</i> , 2020, 11, 2360.	12.8	56
49	Kinetic Modeling and Testâ€Retest Reproducibility of ¹¹ C-EKAP and ¹¹ C-FEKAP, Novel Agonist Radiotracers for PET Imaging of the ^{Î²} -Opioid Receptor in Humans. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1636-1642.	5.0	10
50	Body Mass Index and Age Effects on Brain ¹¹ H-Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography Study. <i>Molecular Imaging and Biology</i> , 2020, 22, 1124-1131.	2.6	9
51	ASSOCIATION BETWEEN CEREBRAL AMYLOID ACCUMULATION AND SYNAPTIC DENSITY IN ALZHEIMER'S DISEASE: A MULTITRACER PET STUDY. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, S123-S124.	1.2	0
52	Synthesis and Preclinical Evaluation of an ¹⁸ F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [¹⁸ F]SynVesT-2. <i>ACS Chemical Neuroscience</i> , 2020, 11, 592-603.	3.5	34
53	Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging. <i>Annals of Neurology</i> , 2020, 87, 329-338.	5.3	112
54	PET imaging of mGluR5 in Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 15.	6.2	29

#	ARTICLE	IF	CITATIONS
55	Tobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1200-1204.	5.0	8
56	Inverse changes in raphe and cortical 5-HT _{1B} receptor availability after acute tryptophan depletion in healthy human subjects. <i>Synapse</i> , 2020, 74, e22159.	1.2	9
57	Separating dopamine D2 and D3 receptor sources of [¹¹ C]-(+)-PHNO binding potential: Independent component analysis of competitive binding. <i>NeuroImage</i> , 2020, 214, 116762.	4.2	9
58	Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand ¹¹ C-UCB-J. <i>EJNMMI Research</i> , 2020, 10, 83.	2.5	8
59	PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases. <i>Neuroscience Letters</i> , 2019, 691, 44-50.	2.1	85
60	The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. <i>Biological Psychiatry</i> , 2019, 86, 864-871.	1.3	27
61	Sex differences in amphetamine-induced dopamine release in the dorsolateral prefrontal cortex of tobacco smokers. <i>Neuropsychopharmacology</i> , 2019, 44, 2205-2211.	5.4	27
62	Effects of age, BMI and sex on the glial cell marker TSPO – a multicentre [¹¹ C]PBR28 HRRT PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2329-2338.	6.4	70
63	S13. IN VIVO EVIDENCE OF REDUCED SYNAPTIC VESICLE DENSITY IN SCHIZOPHRENIA USING [¹¹ C] UCB-J PET IMAGING. <i>Schizophrenia Bulletin</i> , 2019, 45, S310-S311.	4.3	0
64	Synthesis and in vivo evaluation of [¹⁸ F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1952-1965.	6.4	38
65	Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study. <i>Neuropsychopharmacology</i> , 2019, 44, 1720-1727.	5.4	36
66	In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11490-11495.	7.1	34
67	Imaging the Enzyme 11 ^β -Hydroxysteroid Dehydrogenase Type 1 with PET: Evaluation of the Novel Radiotracer ¹¹ C-AS2471907 in Human Brain. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1140-1146.	5.0	11
68	Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers. <i>Neuropsychopharmacology</i> , 2019, 44, 1714-1719.	5.4	22
69	A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. <i>Epilepsia</i> , 2019, 60, 958-967.	5.1	45
70	Lower synaptic density is associated with depression severity and network alterations. <i>Nature Communications</i> , 2019, 10, 1529.	12.8	277
71	Evaluation of ¹¹ C-LSN3172176 as a Novel PET Tracer for Imaging M ₁ Muscarinic Acetylcholine Receptors in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1147-1153.	5.0	17
72	P4481: ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER'S DISEASE: PRELIMINARY EXPERIENCE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1497.	0.8	0

#	ARTICLE	IF	CITATIONS
73	ICâ€Pâ€140: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTIâ€RACER STUDY IN HEALTHY AGING AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P115.	0.8	0
74	Binge alcohol use is not associated with alterations in striatal dopamine receptor binding or dopamine release. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107627.	3.2	7
75	Synthesis and <i>in Vivo</i> Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1544-1554.	3.5	70
76	Quantification of Positron Emission Tomography Data Using Simultaneous Estimation of the Input Function: Validation with Venous Blood and Replication of Clinical Studies. <i>Molecular Imaging and Biology</i> , 2019, 21, 926-934.	2.6	16
77	Age-Related Change in 5-HT ₆ Receptor Availability in Healthy Male Volunteers Measured with ¹¹ C-GSK215083 PET. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1445-1450.	5.0	34
78	Evaluation of PET Brain Radioligands for Imaging Pancreatic Î²-Cell Mass: Potential Utility of ¹¹ C-(+)-PHNO. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1249-1254.	5.0	22
79	Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. <i>Biological Psychiatry</i> , 2018, 84, 413-421.	1.3	43
80	Use of Electronic Cigarettes Leads to Significant Beta2-Nicotinic Acetylcholine Receptor Occupancy: Evidence From a PET Imaging Study. <i>Nicotine and Tobacco Research</i> , 2018, 20, 425-433.	2.6	35
81	The Effect of Treatment with Guanfacine, an Alpha2 Adrenergic Agonist, on Dopaminergic Tone in Tobacco Smokers: An [¹¹ C]FLB457 PET Study. <i>Neuropsychopharmacology</i> , 2018, 43, 1052-1058.	5.4	12
82	Evaluation of the Lysophosphatidic Acid Receptor Type 1 Radioligand ¹¹ C-BMT-136088 for Lung Imaging in Rhesus Monkeys. <i>Journal of Nuclear Medicine</i> , 2018, 59, 327-333.	5.0	16
83	Cortical Î²-amyloid burden, gray matter, and memory in adults at varying APOE Î¼4 risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 61, 207-214.	3.1	28
84	Evaluation of (â€)â€[¹⁸ F]F ₂ ubatineâ€specific binding: Implications for reference region approaches. <i>Synapse</i> , 2018, 72, e22016.	1.2	7
85	Kinetic evaluation and testâ€retest reproducibility of [¹¹ C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 2041-2052.	4.3	143
86	P2â€365: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. <i>Alzheimer's and Dementia</i> , 2018, 14, P832.	0.8	0
87	P1â€469: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P501.	0.8	1
88	2181 Age-related change in 5-HT ₆ receptor availability in healthy male volunteers measured with ¹¹ C-GSK215083 PET. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 3-4.	0.6	0
89	ICâ€04â€03: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P8.	0.8	0
90	ICâ€Pâ€183: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. <i>Alzheimer's and Dementia</i> , 2018, 14, P152.	0.8	0

#	ARTICLE	IF	CITATIONS
91	PET imaging reveals lower kappa opioid receptor availability in alcoholics but no effect of age. <i>Neuropsychopharmacology</i> , 2018, 43, 2539-2547.	5.4	37
92	Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer's Disease: A New Biomarker for Clinical Trials?. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, S145-S146.	1.2	3
93	F149. Preliminary Evidence for Altered Synaptic Density and a Possible Role for Accelerated Ageing in Individuals With MDD as Measured With [11C]UCB-J PET. <i>Biological Psychiatry</i> , 2018, 83, S296.	1.3	4
94	Kappa opioid receptor binding in major depression: A pilot study. <i>Synapse</i> , 2018, 72, e22042.	1.2	26
95	Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. <i>JAMA Neurology</i> , 2018, 75, 1215.	9.0	304
96	Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1095-1107.	4.3	31
97	A multi species evaluation of the radiation dosimetry of [11 C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor. <i>Nuclear Medicine and Biology</i> , 2017, 47, 56-61.	0.6	8
98	Regional and source-based patterns of [11 C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D 2 and D 3 receptor availability in cocaine-use disorder. <i>NeuroImage</i> , 2017, 148, 343-351.	4.2	32
99	Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017, 2, 449-456.	1.5	47
100	Investigating Age Related Associations of Metabotropic Glutamate Receptor 5 Density Using [18 F]FPEB and PET. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, S96-S97.	1.2	1
101	A modification to improve the reliability of ^{11}C CN $^{\sim}$ production in the GE radiochemistry system. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 592-595.	1.0	5
102	The Search for a Subtype-Selective PET Imaging Agent for the GABA _A Receptor Complex: Evaluation of the Radiotracer [^{11}C]ADO in Nonhuman Primates. <i>Molecular Imaging</i> , 2017, 16, 153601211773125.	1.4	8
103	Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8390-8395.	7.1	107
104	962. In-vivo Evidence of Decreased Synaptic Density in Schizophrenia: A [11C]UCB-J PET Imaging Study. <i>Biological Psychiatry</i> , 2017, 81, S389.	1.3	7
105	In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [^{11}C]ABP688 and [^{18}F]FPEB. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 2716-2727.	4.3	49
106	Quantitative projection of human brain penetration of the H ₃ antagonist PF-03654746 by integrating rat-derived brain partitioning and PET receptor occupancy. <i>Xenobiotica</i> , 2017, 47, 119-126.	1.1	5
107	Microglial depletion and activation: A [11C]PBR28 PET study in nonhuman primates. <i>EJNMMI Research</i> , 2017, 7, 59.	2.5	39
108	Quantification of myocardial blood flow with ^{82}Rb : Validation with ^{15}O -water using time-of-flight and point-spread-function modeling. <i>EJNMMI Research</i> , 2016, 6, 68.	2.5	34

#	ARTICLE	IF	CITATIONS
109	Preclinical Evaluation of ¹⁸ F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1448-1453.	5.0	13
110	First-in-Human Assessment of the Novel PDE2A PET Radiotracer ¹⁸ F-PF-05270430. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1388-1395.	5.0	27
111	Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (^{SV} 2A) ligand with preclinical evidence of high brain permeability and fast onset of action. <i>Epilepsia</i> , 2016, 57, 201-209.	5.1	130
112	Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [¹¹ C]-(+)-PHNO. <i>Psychopharmacology</i> , 2016, 233, 3503-3512.	3.1	101
113	Imaging synaptic density in the living human brain. <i>Science Translational Medicine</i> , 2016, 8, 348ra96.	12.4	343
114	Age-related changes in binding of the D2/3 receptor radioligand [¹¹ C](+)PHNO in healthy volunteers. <i>NeuroImage</i> , 2016, 130, 241-247.	4.2	43
115	Receptor Occupancy of the μ -Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer ¹¹ C-LY2795050. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 260-266.	2.5	47
116	OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding. <i>Journal of Affective Disorders</i> , 2016, 196, 87-96.	4.1	38
117	Synthesis and Preclinical Evaluation of ¹¹ C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain. <i>Journal of Nuclear Medicine</i> , 2016, 57, 777-784.	5.0	197
118	PET imaging reveals sex differences in kappa opioid receptor availability in humans, in vivo. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 205-14.	1.0	34
119	Test-Retest Reproducibility of Binding Parameters in Humans with ¹¹ C-LY2795050, an Antagonist PET Radiotracer for the μ Opioid Receptor. <i>Journal of Nuclear Medicine</i> , 2015, 56, 243-248.	5.0	35
120	In Vivo Ketamine-Induced Changes in [¹¹ C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5. <i>Biological Psychiatry</i> , 2015, 77, 266-275.	1.3	82
121	Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 316.	11.0	304
122	Imaging human brown adipose tissue under room temperature conditions with ¹¹ C-MRB, a selective norepinephrine transporter PET ligand. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 747-755.	3.4	25
123	Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 12468-12473.	7.1	265
124	A preliminary study of dopamine D2/3 receptor availability and social status in healthy and cocaine dependent humans imaged with [¹¹ C](+)PHNO. <i>Drug and Alcohol Dependence</i> , 2015, 154, 167-173.	3.2	25
125	Sex Differences in the Brain's Dopamine Signature of Cigarette Smoking. <i>Journal of Neuroscience</i> , 2014, 34, 16851-16855.	3.6	145
126	Kinetic Modeling of ¹¹ C-LY2795050, A Novel Antagonist Radiotracer for PET Imaging of the Kappa Opioid Receptor in Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1818-1825.	4.3	42

#	ARTICLE	IF	CITATIONS
127	Evaluation of ¹¹ C-BU99008, a PET Ligand for the Imidazoline ₂ Binding Sites in Rhesus Brain. <i>Journal of Nuclear Medicine</i> , 2014, 55, 838-844.	5.0	44
128	Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human. <i>Journal of Nuclear Medicine</i> , 2014, 55, 595-601.	5.0	50
129	Imaging Glutamate Homeostasis in Cocaine Addiction with the Metabotropic Glutamate Receptor 5 Positron Emission Tomography Radiotracer [¹¹ C]ABP688 and Magnetic Resonance Spectroscopy. <i>Biological Psychiatry</i> , 2014, 75, 165-171.	1.3	66
130	Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[¹¹ C]O-methylreboxetine. <i>NeuroImage</i> , 2014, 86, 306-310.	4.2	41
131	Evaluation of the agonist PET radioligand [¹¹ C]GR103545 to image kappa opioid receptor in humans: Kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242. <i>NeuroImage</i> , 2014, 99, 69-79.	4.2	54
132	The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [¹¹ C]PBR28 PET study. <i>Brain, Behavior, and Immunity</i> , 2013, 33, 131-138.	4.1	180
133	Studies of the metabotropic glutamate receptor 5 radioligand [¹¹ C]ABP688 with N-acetylcysteine challenge in rhesus monkeys. <i>Synapse</i> , 2013, 67, 489-501.	1.2	42
134	Synthesis and Evaluation of ¹¹ C-LY2795050 as a μ -Opioid Receptor Antagonist Radiotracer for PET Imaging. <i>Journal of Nuclear Medicine</i> , 2013, 54, 455-463.	5.0	80
135	Determination of the In Vivo Selectivity of a New μ -Opioid Receptor Antagonist PET Tracer ¹¹ C-LY2795050 in the Rhesus Monkey. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1668-1674.	5.0	34
136	Tracer Kinetic Modeling of [¹¹ C]AFM, a New PET Imaging Agent for the Serotonin Transporter. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1886-1896.	4.3	17
137	Determination of In Vivo B_{max} and K_d for ¹¹ C-GR103545, an Agonist PET Tracer for μ -Opioid Receptors: A Study in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2013, 54, 600-608.	5.0	31
138	Age Effects on Serotonin Receptor 1B as Assessed by PET. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1411-1414.	5.0	26
139	Affinity and selectivity of [¹¹ C]â€(+)â€PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. <i>Synapse</i> , 2012, 66, 489-500.	1.2	74
140	Evaluation of [¹¹ C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. <i>NeuroImage</i> , 2011, 56, 268-279.	4.2	50
141	[¹¹ C]GR103545: novel one-pot radiosynthesis with high specific activity. <i>Nuclear Medicine and Biology</i> , 2011, 38, 215-221.	0.6	26
142	Assessing the sensitivity of [¹¹ C]p943, a novel 5-HT _{1B} radioligand, to endogenous serotonin release. <i>Synapse</i> , 2011, 65, 1113-1117.	1.2	21
143	PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[¹¹ C]O-methylreboxetine and HRRT. <i>Synapse</i> , 2010, 64, 30-38.	1.2	112
144	Kinetic Modeling of the Serotonin 5-HT _{1B} Receptor Radioligand [¹¹ C]P943 in Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 196-210.	4.3	83

#	ARTICLE	IF	CITATIONS
145	High-resolution imaging of brain 5-HT1B receptors in the rhesus monkey using [11C]P943. Nuclear Medicine and Biology, 2010, 37, 205-214.	0.6	40
146	Dopamine D3 receptor antagonists: The quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5056-5059.	2.2	24
147	[11C]Glycylsarcosine: synthesis and in vivo evaluation as a PET tracer of PepT2 transporter function in kidney of PepT2 null and wild-type mice. Bioorganic and Medicinal Chemistry, 2005, 13, 2993-3001.	3.0	27